The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial
In Chinese people with T2D suboptimally controlled with OADs, once-daily iGlarLixi provided better glycaemic control with BW benefit and lower hypoglycaemia event rates versus IDegAsp.
PDF的下载单位、IP信息已删除
(2025-6-4)
无极微光
极限001
DW
null
invisight
v0id
乐空思
aaaa
152455
xing_xing
Elsevier大王
Nole
复杂珊
酸味yjm
Youdge
子安
初景
GingerF
飘逸的老头
kaio_escolar
皖公网安备34019202002308
